European Psychiatry - Volume 41 - April 2017

601 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S583–S644 S597
1 Universidad Juarez Autonoma de Tabasco, Division Academica
Multidisciplinaria de Comalcalco, Villahermosa, Mexico
2 Hospital Regional de Alta especialidad “Dr. Rodolfo Nieto Padrón”,
Servicio de Citogenética, Villahermosa, Mexico
3 Hospital General de Yajalón- Secretaría de Salud, Servicio de
Pediatría, Yahalón, Chiapas, Mexico
∗ Corresponding author.
The attention deficit hyperactivity disorder (ADHD) is a common
neuropsychiatric disease in infancy and adolescence, its world
prevalence in the general population is high 3.4%. There is genetic
evidence that consistently supports the polygenic nature of ADHD
with a heritability estimated between 75% and 91%; literature
proposes that the brain derived neurotrophic factor (BDNF) is a
candidate gene that participates in the ADHA pathogenesis. One
of the most studied polymorphisms is the Val66Met. The aim of
this study was to determine a family-based an association between
the rs6265, rs122,733,63 and rs110,301,19 polymorphisms of the
BDNF gene and the ADHD in a Mexican population. The ADHD
diagnose was performed by a pedopsychiatrist utilizing the diag-
nostic and statistical manual of mental disorders (DSM-V) who
selected 35 patients; along with the biological parents, a total
of 105 individuals grouped in family-trios (mother, father and
ADHD patient) were studied. Of the 35 probands, 32 were men
and 3 were women (average age 7.7 years; age range 4–14 years).
Subsequently, no statistically significant association was observed
between the BDNF gene polymorphisms and the ADHD etiol-
ogy in Mexican families: rs6265 ( 2 = 1.33; P = 0.24); rs122,733,63
( 2 = 1.33; P = 0.24); rs110,301;19 ( 2 = 0.66; P = 0.41). Further-
more, no preference of transmission was observed for any of the
haplotypes. In conclusion, it was not possible to prove any asso-
ciation between the BDNF gene polymorphic variants and ADHD
in a Mexican population. Future studies comprising larger samples
are necessary to determine the potential role of the BDNF gene in
ADHD.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
e-Poster viewing: Guidelines/guidance
EV0593
Global Level – Elimination of stress,
anxiety and depression at the rate of
25% to 35% (minimum)
M. Ashraf
My Life and The Ultimate Solutions, R & D/Life and Spiritual
Coaching, Lahore, Pakistan
Opening of C.E.P.P.D (Center for Emotional, Personal and Pro-
fessional Development). Almost every child in the world joins
school and as per policy and procedures school staff/teachers
develop their educational level but emotional health is not in
focus at all; therefore child raised up with many severe negative
and self-defeating behaviors; they understand others but oth-
ers not understand them and that’s the beginning all problems
start from here. . .. The Center will provide state of the art guide-
lines/guidance (one stop solutions) supporting facilities starting
from schooling onward throughout entire life for people belongs
to all walks of life. In these centers anyone can go and will come
out with clear head and in hand solutions, team of profession-
als shall provide guidance and support to everyone for healthy
and balanced life by all means and will also develop alumni net-
working for permanent intact and fund raising on continuous basis
from all over the world. C.E.P.P.D will play central and synergizing
role between all sectors (for instance, schools, colleges, universi-
ties, counseling, vocational, community, hospitals, NGOs, mental
and emotional health centers, child up-bringing, parenting, career
counseling, soft skills training’s; likewise list is on.... along with
financial assistance from Govt. and semi-government sectors, will
share implementation details as needed/at the time of sympo-
sium/brain storming sessions. These centers will become surely
The turning point center in city than progress in next cities; like-
wise in country than at global level and yes together positively we
can set landmark by mainly utilizing the medium of education and
guidance.
Disclosure of interest The author has not supplied his declaration
of competing interest.
e-Poster viewing: Intellectual disability
EV0594
Pregabalin use in adults with
intellectual disabilities
K. Courtenay ∗, S. Jaydeokar , B. Perera
1 UCL, Division of Psychiatry, London, United Kingdom
2 Cheshire and Wirral Foundation Trust, Department Intellectual
Disabilities, Cheshire, United Kingdom
3 Barnet Enfield Haringey Mental Health NHS Trust, Department
Intellectual Disabilities, London, United Kingdom
∗ Corresponding author.
Introduction Pregabalin is a well-established anti-epileptic drug
in the treatment of epilepsy. It is also indicated for the treatment
of generalised anxiety disorder and neuropathic pain. In addition,
it has mood modulating properties. In people with intellectual dis-
abilities it is used to treat epilepsy. There is little evidence of the
use of pregabalin in managing mental health difficulties in people
with intellectual disabilities.
Objectives To describe the use of pregabalin in adults with intel-
lectual disabilities.
Method A descriptive case series of adults with intellectual dis-
abilities living in the community, under the care of a community
psychiatrist, who are prescribed Pregabalin. Outcomes of treatment
were measured using the health of the nation outcome scale for
people with intellectual disabilities (HoNOS-LD).
Results Fourteen cases were identified in the community service
of adults with Intellectual Disabilities. Twelve were men and two
were women. The average age of the sample was 29 years. The
range in duration of using pregabalin was from 3 to 72months.
Thirteen adults had a diagnosis of Autism of which three also
had ADHD. The indications for using pregabalin and numbers
were : anxiety (12); liability of mood (2); generalised anxi-
ety disorder (1); epilepsy (1). The daily dose range was from
150mg to 300mg The mean change in HoNOS-LD scores was
32%.
Conclusions Pregabalin is a useful treatment in people with intel-
lectual disabilities who experience anxiety. It is especially effective
among adults with ID and autism to modulate mood and anxiety
symptoms.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.